The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04945031

Enrollment

317

Registered

2021-06-30

Start date

2019-11-08

Completion date

2020-12-31

Last updated

2021-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis

Brief summary

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Interventions

OTHERcannabis

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Inclusion criteria

* Patients ≥ 12 years of age * Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5 * Patients had history of use of cannabis in medical chart * Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion criteria

* Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6 * Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test * Patients who cancel of medical treatment before 7 day after admission.

Design outcomes

Primary

Measure	Time frame	Description
Pharmacological treatment pattern for cannabis-induced psychosis	30 days	Pharmacological treatment pattern for cannabis-induced psychosis during admission

Secondary

Measure	Time frame	Description
Change of Brief psychiatric rating scale (BPRS) form the first day of admission	Day1, Day 8, Day 15 and Day 22	A high BPRS score is more severe of symptoms than a lower score

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026